In that report, local treatment with dual-specificity NK cells was superior to treatment with the corresponding monospecific CAR-NK cells in immunodeficient mice carrying intracranial GBM xenografts expressing EGFR, EGFRvIII, or both. The gene discussed is EGFR; the disease is glioblastoma.